Immunotherapy Resistance and Failure Presentation Application Guide
# SITC 2020 Immunotherapy Resistance and Failure Presentation Application Guide

## Table of Contents

- **Immunotherapy Resistance and Failure Program Overview** .......................................................... 1
  - Program Purpose .................................................................................................................................. 1
  - Program Organizers ................................................................................................................................. 1
  - Target Audience ........................................................................................................................................ 1
  - Learning Objectives .................................................................................................................................. 2
  - Reasons to Submit an Application ........................................................................................................... 2

- **Application Submission Information** .............................................................................................. 3
  - Submitting an Application ......................................................................................................................... 3
  - Application Submission Deadline ............................................................................................................ 3
  - Abstract Submission Criteria ..................................................................................................................... 3
  - Application ................................................................................................................................................ 3

- **Important Application Dates** ........................................................................................................... 4

- **Application Guidelines** ..................................................................................................................... 5
  - Submission Guidelines .............................................................................................................................. 5
  - Annual Meeting Abstract Submission ........................................................................................................ 5

- **Application Presentation Information** ............................................................................................. 6
  - Application Presentation Guidelines ........................................................................................................ 6
  - Faculty Guidelines and Information .......................................................................................................... 6

- **Application Policies** ............................................................................................................................ 8
  - Press Release Policy ................................................................................................................................. 8
  - Withdrawal and Editing Policy .................................................................................................................. 8
SITC Immunotherapy Resistance and Failure Program Overview

The Immunotherapy Resistance and Failure is part of SITC’s 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) and will be held on Nov. 9, 2020.

Program Purpose

While many patients with cancer are experiencing significant long-term benefits from immune checkpoint inhibitors (ICIs), the vast majority exhibit either primary or secondary (acquired) resistance to these therapies. The underlying mechanisms for the wide range of responses are not well understood. Before ICI resistant/relapsed patients can be properly managed, however, these underlying causes need to be elucidated, which will enable rational design of therapeutic options based on these mechanisms of resistance. Testing of therapies in this ICI-resistant population also presents unique questions, including defining resistance and proper clinical trial design strategies.

Addressing the problem of ICI resistance and failure therefore will require collaboration between researchers and clinicians involved in all aspects of cancer research and practice, including basic, translational, and clinical areas. This program will feature both invited faculty presentations by experts in the field, as well as abstract presentations from researchers, who will apply for consideration for oral presentation. These presentations will be interspersed throughout the program. Session topics will include defining immune checkpoint inhibitor resistance, primary resistance, secondary/acquired resistance, and therapeutic strategies for patients with resistant disease. This workshop will bring together all stakeholders to address ICI resistance and failure, in order to move the field forward and continue advancing patient care.

Program Organizers

This program is organized in collaboration with the SITC Industry Committee. The following individuals are recognized for their leadership in developing this program:

- Kald Abdallah, MD, PhD – Bristol-Myers Squibb
- Edward Cha, MD, PhD – Genentech
- Jennifer Gansert, MD, PhD – Amgen
- Israel Lowy, MD, PhD – Regeneron Pharmaceuticals
- Giovanni Melillo, MD - AstraZeneca
- Eric Rubin, MD – Merck & Co., Inc.

Target Audience

The target audience for this program includes researchers from academia and industry involved in basic, translational and clinical cancer research, as well as clinicians and those from regulatory and funding agencies.
Learning Objectives

At the conclusion of this activity, participants should be able to:

- Describe patterns of both primary and acquired resistance to immune checkpoint inhibitors
- Summarize current understanding of biological mechanisms of immune checkpoint inhibitor resistance
- Outline rational therapeutic strategies for patients with immune checkpoint inhibitor-resistant disease

Reasons to Submit Your Application to the Immunotherapy Resistance and Failure Program

- Multiple oral presentation opportunities available
- Poster presentation opportunities available during networking reception
- The opportunity to present and discuss your research with luminaries in the immunotherapy field
Application Submission Information

Submitting an Application

Industry and academic investigators who are working on immunotherapy resistance and failure are welcome to submit an application describing their research for the opportunity to present during the Immunotherapy Resistance and Failure Pre-Conference Program.

To submit a presentation application, please click here.

Application Submission Deadline

**August 25, 2020 by 5 p.m. PDT**: Deadline to submit presentation applications.

Application Submission Criteria

Application reviewers consider a number of variables in reviewing and selecting the applications for presentation, including, but not limited to, the following criteria:

- Content in your presentation must be available to publicly present by Nov. 9, 2020.

Presentations should address one or more of the following topics:

- Mechanisms of immune checkpoint inhibitor resistance or failure
- Clinical and/or translational data regarding immune checkpoint inhibitor resistance or failure
- Therapeutic strategies for overcoming immune checkpoint inhibitor resistance or failure - with focus on specific targets and combinations

Preference will be given to presentation application submissions with the following:

- Has minimal overlap with other presentation applications
- Has not been presented elsewhere or has significant changes to the submission since last being presented/published
- Has basic research, translational and/or clinical data

Application

Please provide a short description of your research and results, limited to one page.
## Important Application Dates

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 1, 2020</td>
<td>Immunotherapy Resistance and Failure Presentation Application Submission Site Opens</td>
</tr>
<tr>
<td>August 25, 2020</td>
<td>Immunotherapy Resistance and Failure Presentation Application Submission Site Closes</td>
</tr>
<tr>
<td>September 25, 2020</td>
<td>Immunotherapy Resistance and Failure Presentation Application Notifications Sent</td>
</tr>
<tr>
<td>September 30, 2020</td>
<td>Accepted Application Presentation Confirmations Due and Deadline for Withdrawals and Changes</td>
</tr>
<tr>
<td>September 30, 2020</td>
<td>Presenter Information and Registration for Accepted Applications Due</td>
</tr>
<tr>
<td>October 15, 2020</td>
<td>Presentation Slides and Recording Permission for Accepted Application Presenters Due</td>
</tr>
<tr>
<td>November 9, 2020</td>
<td>Immunotherapy Resistance and Failure Pre-Conference Program</td>
</tr>
<tr>
<td>November 9-14 2020</td>
<td>35th Anniversary Annual Meeting &amp; Pre-Conference Programs</td>
</tr>
</tbody>
</table>
Application Guidelines

Submission Guidelines
Below are the guidelines for application submission. The submitting author is responsible for assuring that the application adheres to these.

Title
The title should be entered exactly as it should appear in the program and should be in sentence case. Do not put the title in quotes, underline it, or put periods at the end. The title can be a maximum of 200 characters, including spaces.

Example: Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer

Presenters
Submitters will be asked to include information about the presenter if the application is accepted for presentation. Please enter the information about the presenter.

- If the application submitter will be the presenter, the submitter can simply update their role by clicking on “Submitter Only,” selecting “Presenter” and clicking Save.
- If the submitter will not be the presenter, the submitter should keep “Submitter Only” as their Role and click “Add Person” to add the presenter

Annual Meeting Abstract Submission
Please note, applications submitted for the Immunotherapy Resistance and Failure program DO NOT qualify as a 35th Anniversary Annual Meeting abstract submission; however, you may submit your work to both programs by completing both a presentation application submission and an abstract submission. If you are interested in submitting your work as a formal abstract to the 35th Anniversary Annual Meeting, Nov. 11-14, 2020, you can do so by going here.
Application Presentation Information

After applications are reviewed and selected, application submitters will be sent an email notification stating whether the application was accepted. Within the notification for accepted applications, the application submitter will also be asked to accept or decline participation in the Immunotherapy Resistance and Failure program. If we do not receive a response by Sept. 30, 2020 we will assume you accept and include the application in all publications.

Presentation Guidelines
Registration
The presenter must register for the Immunotherapy Resistance and Failure program to present. Submitting an application does not register them for the meeting.

Application Presentations
All applications chosen for presentation will present on Monday, Nov. 9. Presentations are 10 minutes long with another 5 minutes for question and answer.

The designated application presenter will be added to the SITC speaker management system upon confirming participation in the program to collect all required information. Application presenters will be required to submit a conflict of disclosure form, a recording permission form, a photo, and a biography as well as submit presentation slides prior to the Annual Meeting.

Prior to the program, all presenters will be contacted with the final program information so that they may communicate with their moderating Organizer and other presenters. Some Organizers may schedule a conference call to review the presentations and group discussions, others may communicate via email. All presenters are required to be responsive to the requests of the program Organizers and SITC staff.

Faculty Guidelines and Information
Guidelines
Please take into consideration the following guidelines when creating and presenting your talk for this educational activity. These guidelines were created to help ensure that presentations give a balanced viewpoint to learners that is free of commercial bias.

- Faculty will disclose to SITC all relevant financial relationships, and hereby allow SITC to disclose this information to learners in print.
- Presentations and/or content will need to be reviewed prior to the activity. Educational content and resources must be submitted in advance. Presentations/content is due Oct. 15.
- The content and/or presentation of the information with which you are involved, including any presentation of therapeutic options, is expected to be well-balanced, evidence-based and unbiased. It will promote quality or improvements in healthcare and will not promote a specific proprietary business interest of a commercial interest.
- If faculty are presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.
- If faculty have been trained or utilized by a commercial entity or its agent as a speaker (i.e., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.
- If faculty provide recommendations involving clinical medicine, they will be based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients. All scientific research relating to this activity in support of a patient care recommendation will conform to the generally accepted standards of experimental design, data collection, and analysis.
- If faculty discuss specific health care products or services, they are to use generic names to the extent possible. If necessary to mention trade names, faculty will use trade names from several different companies when available.
- If faculty discuss any product use that is off-label or investigational, they are to disclose that the use or indication in question is not currently approved by the FDA. Please state in presentations, “There will OR will not be discussion about the use of products for non-FDA approved indications in this presentation.”
- Faculty have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with SITC specific to this particular presentation for the SITC educational activity.
- A monitor will be attending the event to ensure that all presentations are educational, and not promotional, in nature.

Faculty Information

- Presentation Requirements: All presentations must be in 16:9 aspect ratio. All Faculty must also have a disclosure slide in the beginning of their presentation, even if just to state that there are no relevant disclosures to the presentation. If faculty intend to discuss any product use that is off-label or investigational, they must disclose that the use or indication in question is not currently approved by the FDA. Faculty must include the following sentence on their disclosure slide: “There will OR will not be discussion about the use of products for non-FDA approved indications in this presentation.” Please use the 35th Anniversary Annual Meeting slide template for creating your PowerPoint presentation.
- Recording Permissions: To advance the field, SITC requests you complete a recording permission form to give us permission to post your slides on the Society’s website and/or to prepare audio-visual (AV) recordings of your presentation for production, online hosting, and distribution as webinars and/or other electronic media. These enduring materials greatly extend the educational impact and reach of the meeting.
Application Policies

Below are the policies of the SITC application submission process. By submitting an abstract, you are agreeing to abide by these policies.

Press Release Policy
Any planned press releases and media alerts must be reviewed and approved in advance by SITC Communications staff. Please provide a minimum of two business days for review. Drafts should be emailed to communications@sitcancer.org.

Withdrawal & Editing Policy
The deadline for presentation application withdrawal or changes, including presenter changes, is Sept. 30, 2020. This deadline is set in place because the application information is pulled for publication immediately following this date and cannot be edited after that. If you would like to withdraw or make a change to your application between the submission deadline and this date, you must submit your request in writing to education@sitcancer.org. Upon receipt of your request we will make the change, if possible, and send a confirmation once the withdrawal or change has been completed.